2021
DOI: 10.1038/s41408-021-00469-5
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The emergence of various novel therapies over the last decade has changed the therapeutic landscape for multiple myeloma. While the clinical outcomes have improved significantly, the disease remains incurable, typically in patients with relapsed and refractory disease. Chimeric antigen receptor (CAR) T-cell therapies have achieved remarkable clinical success in B-cell malignancies. This scope of research has more recently been extended to the field of myeloma. While B-cell maturation antigen (BCMA) is currentl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
89
0
6

Year Published

2021
2021
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 100 publications
(95 citation statements)
references
References 107 publications
0
89
0
6
Order By: Relevance
“…With the latter, cilta-cel compared to ide-cel and orva-cel could increase its binding affinity even in MM cells with low BCMA expression, resulting in lower CAR-T cell doses and in a delay of the median time of onset of CRS, with 1–2 days vs. 7 days (ide-cel vs. cilta-cel). These effects allow the management of cilta-cel infusion in outpatients following hospital admission after 5 days to monitor potential CRS [ 84 , 85 ].…”
Section: Bmca-targeted Treatment In MMmentioning
confidence: 99%
“…With the latter, cilta-cel compared to ide-cel and orva-cel could increase its binding affinity even in MM cells with low BCMA expression, resulting in lower CAR-T cell doses and in a delay of the median time of onset of CRS, with 1–2 days vs. 7 days (ide-cel vs. cilta-cel). These effects allow the management of cilta-cel infusion in outpatients following hospital admission after 5 days to monitor potential CRS [ 84 , 85 ].…”
Section: Bmca-targeted Treatment In MMmentioning
confidence: 99%
“…BCMA has a crucial role in the survival of long-lived plasma cells in the bone marrow and is not expressed in other vital tissues [93]. There are several BCMA CAR T-cell products in clinical development whose differences and clinical activity are reviewed elsewhere [95,96]. So far, only one of them, idecabtagene vicleucel, has received FDA approval based on recently published results from a phase 2 study (NCT03361748) [97,98], and ciltacabtagene autoleucel has earned FDA priority review [99], both for the indication of relapsed/refractory MM.…”
Section: Anti-bcma Car T-cell Therapymentioning
confidence: 99%
“…The potential risk of relapse due to antigen escape and intratumoral heterogeneity with BCMA-negative subclones underscore the importance of targeting additional multiple myeloma-associated cell surface antigens. Several CAR T-cell products specific for other antigens, such as CD19, CD38, CD138, CD229, SLAMF7, and GPRC5D, are currently being evaluated in preclinical or clinical studies, and are reviewed elsewhere [95,96]. In addition, dual-antigen targeting combining BCMA with some alternative targets in bispecific CAR constructs proved an ability to prevent antigen escape in a mouse model [104,105].…”
Section: Resistance To Anti-bcma Car T-cell Therapymentioning
confidence: 99%
“…Six out of ten demonstrated very good partial response, two achieved partial response, and two did not respond leading to disease progression [ 27 ]. Dual antigen-targeting therapy with anti-CD19/anti-BCMA showed a 100% overall response rate [ 28 ].…”
Section: Reviewmentioning
confidence: 99%